Overall prevalence, n (%) | 210 (7.11) | 2743 (92.89) | | 63 (2.13) | 2890 (97.87) | | 21 (0.71) | 2932 (99.29) | |
COPD prevalence, n (%) | 23 (10.95) | 154 (5.61) | 0.003 | 13 (20.63) | 164 (5.67) | <0.001 | 8 (38.10) | 169 (5.76) | <0.001 |
Prebronchodilator lung function, mean±SD |
FVC (L) | 3.18±1.01 | 3.45±1.00 | <0.001 | 3.04±0.99 | 3.44±1.00 | 0.002 | 2.61±0.85 | 3.44±1.00 | <0.001 |
FEV1 (L) | 2.40±0.79 | 2.67±0.77 | <0.001 | 2.20±0.79 | 2.66±0.78 | <0.001 | 1.71±0.67 | 2.66±0.78 | <0.001 |
FEV1/height2 (L/m2) | 0.99±0.27 | 1.08±0.25 | <0.001 | 0.91±0.28 | 1.07±0.25 | <0.001 | 0.73±0.27 | 1.07±0.25 | <0.001 |
FEV1/FVC (%) | 75.57±9.31 | 77.55±6.62 | 0.003 | 71.89±11.19 | 77.53±6.69 | <0.001 | 64.94±12.81 | 77.50±6.73 | <0.001 |
Postbronchodilator lung function, mean±SD |
FVC (L) | 3.27±1.00 | 3.49±0.98 | 0.002 | 3.21±0.99 | 3.48±0.99 | 0.032 | 2.85±0.91 | 3.48±0.99 | 0.005 |
FEV1 (L) | 2.56±0.80 | 2.80±0.79 | <0.001 | 2.42±0.80 | 2.79±0.79 | <0.001 | 1.99±0.73 | 2.79±0.79 | <0.001 |
FEV1/height2 (L/m2) | 1.06±0.27 | 1.13±0.25 | <0.001 | 1.00±0.28 | 1.12±0.25 | <0.001 | 0.85±0.29 | 1.12±0.25 | <0.001 |
FEV1/FVC (%) | 78.49±8.69 | 80.24±6.18 | 0.005 | 75.22±10.29 | 80.22±6.25 | <0.001 | 69.65±13.05 | 80.19±6.27 | 0.001 |
Respiratory symptoms, n (%) |
Dyspnoea on exertion | 61 (29.04) | 204 (7.43) | <0.001 | 28 (44.44) | 237 (8.20) | <0.001 | 10 (47.62) | 255 (8.70) | <0.001 |
Hospitalisation in last 12 months due to respiratory symptoms | 6 (2.86) | 12 (0.43) | <0.001 | 5 (7.94) | 13 (0.45) | <0.001 | 4 (19.10) | 14 (0.48) | <0.001 |
Missed working days in the last 12 months due to respiratory symptoms | 28 (13.33) | 45 (1.64) | <0.001 | 15 (23.81) | 58 (2.00) | <0.001 | 8 (38.10) | 65 (2.21) | <0.001 |